Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remazolam Besylate vs Midazolam for Sedation in Sepsis
NCT06731088Phase 4Enrolling by invitation
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in sepsis (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: The number of days without delirium or coma during the 14-day intervention period. Started Jan 2025; status: enrolling by invitation.
02
Drugs
remimazolam
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06731088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731088.